Literature DB >> 14611747

Proteinuria in diabetic nephropathy: treatment and evolution.

Ruth C Campbell1, Piero Ruggenenti, Giuseppe Remuzzi.   

Abstract

Diabetic nephropathy is characterized by increased urinary albumin excretion and loss of renal function. Increased urinary albumin (proteinuria) is a key component of this disease. Previously, its development led to end-stage renal disease with increased mortality and morbidity for diabetic patients versus nondiabetic patients. Several treatment strategies currently exist that can prevent, slow, and even reverse diabetic nephropathy. New trials suggest that a multidisciplinary approach focused on optimizing metabolic and hypertensive control, in addition to the use of angiotensin-converting enzyme inhibitors or angiotensin 2 receptor antagonists, is effective in halting the progression of disease. Screening and implementation of these strategies is needed to reverse the epidemic of diabetic renal disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14611747     DOI: 10.1007/s11892-003-0014-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   5.430


  71 in total

Review 1.  Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

Authors:  N Ismail; B Becker; P Strzelczyk; E Ritz
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

2.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.

Authors:  E R Seaquist; F C Goetz; S Rich; J Barbosa
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

Review 3.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

4.  Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury.

Authors:  B R Dunn; R Zatz; H G Rennke; T W Meyer; S Anderson; B M Brenner
Journal:  J Hypertens Suppl       Date:  1986-12

5.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.

Authors:  W A Wilmer; L A Hebert; E J Lewis; R D Rohde; F Whittier; D Cattran; A S Levey; J B Lewis; S Spitalewitz; S Blumenthal; R P Bain
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

6.  Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.

Authors:  S N Wang; J LaPage; R Hirschberg
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

7.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

8.  Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.

Authors:  P Ruggenenti; L Mosconi; F Sangalli; F Casiraghi; V Gambara; G Remuzzi; A Remuzzi
Journal:  Kidney Int       Date:  1999-03       Impact factor: 10.612

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy.

Authors:  Henrik Post Hansen; Ellis Tauber-Lassen; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

View more
  8 in total

Review 1.  Compelling drug indications in diabetic and nondiabetic nephropathy.

Authors:  Eberhard Ritz; Ralf Dikow; Martin Zeier
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

2.  Gas1 expression in parietal cells of Bowman's capsule in experimental diabetic nephropathy.

Authors:  Brenda I Luna-Antonio; Rafael Rodriguez-Muñoz; Carmen Namorado-Tonix; Paula Vergara; Jose Segovia; Jose L Reyes
Journal:  Histochem Cell Biol       Date:  2017-03-18       Impact factor: 4.304

3.  Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients.

Authors:  Carla Harkin; Diego Cobice; Simon Brockbank; Stephanie Bolton; Frances Johnston; Anna Strzelecka; Joanne Watt; Mary Jo Kurth; John V Lamont; Peter Fitzgerald; Tara Moore; Mark W Ruddock
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

4.  The Effects of Salvianolate Combined With Western Medicine on Diabetic Nephropathy: A Systematic Review and Meta-Analysis.

Authors:  Yuehong Shen; Shulin Wang; Yuanyuan Liu; Ling Ge; Lili Xia; Xiaoxiao Zhang; Yuying Miao; Jianping Shen; Qian Zhou
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

5.  Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy.

Authors:  John M Flack; Karl Duncan; Suzanne E Ohmit; Ruth Quah; Xuefeng Liu; Preeti Ramappa; Sandra Norris; Lowell Hedquist; Amanda Dudley; Samar A Nasser
Journal:  Vasc Health Risk Manag       Date:  2007

Review 6.  New insight into the molecular drug target of diabetic nephropathy.

Authors:  Vivian Soetikno; Wawaimuli Arozal; Melva Louisa; Rianto Setiabudy
Journal:  Int J Endocrinol       Date:  2014-02-04       Impact factor: 3.257

7.  Wogonin Ameliorates Renal Inflammation and Fibrosis by Inhibiting NF-κB and TGF-β1/Smad3 Signaling Pathways in Diabetic Nephropathy.

Authors:  Zhi-Chao Zheng; Wei Zhu; Lei Lei; Xue-Qi Liu; Yong-Gui Wu
Journal:  Drug Des Devel Ther       Date:  2020-10-08       Impact factor: 4.162

Review 8.  Accelerated Kidney Aging in Diabetes Mellitus.

Authors:  Jing Guo; Hui Juan Zheng; Wenting Zhang; Wenjiao Lou; Chenhui Xia; Xue Ting Han; Wei Jun Huang; Fan Zhang; Yaoxian Wang; Wei Jing Liu
Journal:  Oxid Med Cell Longev       Date:  2020-07-27       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.